| IMGC936, a first-in-class ADAM9-targeting antibody-drug conjugate, demonstrates promising anti-tumor activity S Hicks, D Loo, K Sinkevicius, J Scribner, B Barat, N Yoder, C Espelin, ... Cancer Research 79 (13_Supplement), 1533-1533, 2019 | 2 | 2019 |
| CX-2043, an EpCAM-targeting probody drug conjugate, demonstrates anti-tumor activity with a favorable safety profile in preclinical models B Liu, J Shen, W Yu, C Jing, S Saha, V Rangan, J Richardson, Y Liu, ... European Journal of Cancer 138, S15, 2020 | 1 | 2020 |
